Author(s): Rini BI, Shaw V, Rosenberg, Kim ST, Chen I
A complete response (CR) to therapy in patients with metastatic renal cell carcinoma (RCC) is rare but has been achieved in a minority of patients using high-dose interleukin-2. Surgical CR after partial response to immunotherapy in metastatic RCC has been anecdotally reported, although the low overall response rate to cytokines precludes this procedure in the majority of patients. Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor with antiangiogenic and antitumor activity. Clinical efficacy has been demonstrated, with high objective response rates observed in a variety of solid tumor types, including RCC. Herein, we report 2 cases of patients with cytokine-refractory metastatic RCC who received sunitinib and achieved sufficient decrease in tumor burden to permit subsequent surgical resection, resulting in long-term CR.
Author(s): Staehler MD, Kruse J, Haseke N, Stadler T, Roosen A, et al.
Author(s): Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, et al.
Author(s): Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, et al.
Author(s): Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, et al.
Author(s): Deguchi M, Shiina H, Igawa M, Kaneuchi M, Nakajima K, et al.
Author(s): Stoehr C, Burger M, Stoehr R, Bertz S, Ruemmele P, et al.
Author(s): Altavilla G, Fassan M, Busatto G, Orsolan M, Giacomelli L
Author(s): Leach FS, Koh M, Sharma K, McWilliams G, Talifero-Smith L, et al.
Author(s): Haugaard A, Pei Y, Fan Y, Cong Z
Author(s): Le D, Uram J, Wang H, Bartlett BR, Kemberling H, et al.
Author(s): Kelderman S, Schumacher TN, Kvistborg P